OBLN vs. INFU, NSPR, TMDIF, PETV, HSAQ, RVP, CTCX, GBS, BTCY, and IVF
Should you be buying Obalon Therapeutics stock or one of its competitors? The main competitors of Obalon Therapeutics include InfuSystem (INFU), InspireMD (NSPR), Titan Medical (TMDIF), PetVivo (PETV), Health Sciences Acquisitions Co. 2 (HSAQ), Retractable Technologies (RVP), Carmell (CTCX), GBS (GBS), Biotricity (BTCY), and INVO Fertility (IVF). These companies are all part of the "medical" sector.
Obalon Therapeutics vs. Its Competitors
Obalon Therapeutics (NASDAQ:OBLN) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.
InfuSystem has higher revenue and earnings than Obalon Therapeutics.
In the previous week, InfuSystem had 2 more articles in the media than Obalon Therapeutics. MarketBeat recorded 2 mentions for InfuSystem and 0 mentions for Obalon Therapeutics. Obalon Therapeutics' average media sentiment score of 0.00 beat InfuSystem's score of -0.50 indicating that Obalon Therapeutics is being referred to more favorably in the media.
Obalon Therapeutics has a beta of -1.23, suggesting that its share price is 223% less volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.79, suggesting that its share price is 79% more volatile than the S&P 500.
InfuSystem has a consensus target price of $13.50, suggesting a potential upside of 45.32%. Given InfuSystem's stronger consensus rating and higher probable upside, analysts plainly believe InfuSystem is more favorable than Obalon Therapeutics.
18.6% of Obalon Therapeutics shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 8.1% of Obalon Therapeutics shares are held by insiders. Comparatively, 11.4% of InfuSystem shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
InfuSystem has a net margin of 1.12% compared to Obalon Therapeutics' net margin of -776.76%. InfuSystem's return on equity of 2.78% beat Obalon Therapeutics' return on equity.
Summary
InfuSystem beats Obalon Therapeutics on 14 of the 16 factors compared between the two stocks.
Get Obalon Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OBLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Obalon Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:OBLN) was last updated on 10/17/2025 by MarketBeat.com Staff
